US4716178A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted di-t-butylphenols
Assignee: Riker Laboratories Inc
•
Filing: 1986-08-27
•
Granted: 1987-12-29
•
Expires: 2006-08-27
Abstract
Abstract Novel compounds which are 2,6-di-t-butylphenols substituted on the 4 position by an anilino group, which anilino group is substituted by a group which includes carboxyl, tetrazolyl or N-methyltetrazolyl are useful as inhibitors of leukotriene synthesis and as antiallergic agents. Pharmaceutical compositions containing such compounds and pharmacological methods for use of such compounds are also disclosed.
Inventors
- 👤 Robert A. Scherrer
- 👤 Mark A. Rustad
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 16:25
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04; A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; C07C; C07C233/00; C07C233/01; C07C233/16
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
242 words
A compound of the formula ##STR3## wherein each R independently represents hydrogen, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino, di(lower)alkylamino, hydroxy, lower acylamido, trifluoromethyl, benzoyloxy, carboxy, or a derivative of a compound wherein R is carboxy selected from a lower alkyl carboxylate ester, a (lower)alkylamino(lower)alkyl carboxylate ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt, and a pharmaceutically acceptable carboxylate salt; and n is 0, 1, 2 or 3, with the proviso that if n is 2 or 3, only one R substituent, at the most, is selected from carboxy, and further with the proviso that if n is 2 or 3, all R substituents combined contain no more than 6 carbon atoms; Z is a carbon-carbon bond, divalent alkyl of 1 to about 8 carbon atoms or divalent alkylene of 2 to about 8 carbon atoms, and when alkyl or alkylene, Z may optionally be substituted by methyl or phenyl and may contain an ether, thioether or phenylene linkage; A is selected from carboxyl, tetrazolyl, and N-methyl tetrazolyl, with the proviso that if Z is a carbon-carbon bond, A is carboxyl; or a derivative of the foregoing selected from a lower alkyl carboxylate ester, a (lower)alkylamino(lower)alkyl carboxylate ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl carboxylate ester acid-addition salt and a pharmaceutically acceptable carboxylate salt of the carboxy moiety when A is carboxyl, and selected from a pharmaceutically acceptable alkali metal and an alkaline earth salt of the tetrazolyl moiety when A is tetrazolyl.
Claim 2
Dependent Claim
242 words
A compound of the formula ##STR3## wherein each R independently represents hydrogen, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino, di(lower)alkylamino, hydroxy, lower acylamido, trifluoromethyl, benzoyloxy, carboxy, or a derivative of a compound wherein R is carboxy selected from a lower alkyl carboxylate ester, a (lower)alkylamino(lower)alkyl carboxylate ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt, and a pharmaceutically acceptable carboxylate salt; and n is 0, 1, 2 or 3, with the proviso that if n is 2 or 3, only one R substituent, at the most, is selected from carboxy, and further with the proviso that if n is 2 or 3, all R substituents combined contain no more than 6 carbon atoms; Z is a carbon-carbon bond, divalent alkyl of 1 to about 8 carbon atoms or divalent alkylene of 2 to about 8 carbon atoms, and when alkyl or alkylene, Z may optionally be substituted by methyl or phenyl and may contain an ether, thioether or phenylene linkage; A is selected from carboxyl, tetrazolyl, and N-methyl tetrazolyl, with the proviso that if Z is a carbon-carbon bond, A is carboxyl; or a derivative of the foregoing selected from a lower alkyl carboxylate ester, a (lower)alkylamino(lower)alkyl carboxylate ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl carboxylate ester acid-addition salt and a pharmaceutically acceptable carboxylate salt of the carboxy moiety when A is carboxyl, and selected from a pharmaceutically acceptable alkali metal and an alkaline earth salt of the tetrazolyl moiety when A is tetrazolyl.
Claim 3
Dependent Claim
11 words
A compound according to claim 1, wherein each R is hydrogen.
Claim 4
Dependent Claim
20 words
A compound according to claim 1, selected from 5-(3,5-di-t-butyl-4-hydroxy-N-phenylanilino)-5-oxopentanoic acid, 4-(3,5-di-t-butyl-4-hydroxy-N-phenyl-anilino)-4-oxobutanoic acid, N-(3,5-di-t-butyl-4-hydroxyphenyl)-N-phenyl-2-carboxyphenylacetamide, N-(3-carboxyphenyl)-N-(3,5-di-t-butyl-4-hydroxyphenyl)succinamic acid, 4-[N-(3,5-di-t-butyl-4-hydroxyphenyl)-N-phenylcarbamoyl]-3-methylbutyric acid, and N-(3,5-di-t-butyl-4-hydroxyphenyl)-N-phenylmaleamic acid.
Claim 5
Dependent Claim
32 words
An antiallergic pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable vehicle, said compound being present in an amount effective for obtaining an antiallergic response in a mammal.
Claim 6
Dependent Claim
33 words
A method for inhibiting bronchoconstriction due to an allergic response in a mammal wherein a compound according to claim 1 is administered to said mammal in an amount effective for obtaining such inhibition.
Claim 7
Dependent Claim
13 words
A method according to claim 5, wherein said compound is administered by inhalation.
Claim 8
Dependent Claim
12 words
A method according to claim 5, wherein said compound is administered orally.
Claim 9
Dependent Claim
28 words
A method for inhibiting leukotriene synthesis in a mammal comprising administering to said mammal a compound according to claim 1 in an amount effective to inhibit said synthesis.
Claim 10
Dependent Claim
28 words
A method for inhibiting lipoxygenase activity in a mammal comprising administering to said mammal a compound according to claim 1 in an amount effective to inhibit said activity.
References Cited (Backward Citations)
US3313848A
Cited
US3773936A
Cited
FR2098587A5
Cited
US3766280A
Cited
US4070484A
Cited
US4153728A
Cited
US4172151A
Cited
US4420115A
Cited
US4568684A
Cited
US4496590A
Cited
US4515980A
Cited
US4510139A
Cited
US4528392A
Cited
EP0181568A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-12-28 | 1991-06-29 | 1991-12-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-12-28 | 1995-06-29 | 1995-12-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-12-28 | 1999-06-29 | 1999-12-29 | $7700.00 | Window Closed / Lapsed |